Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023 2023-10-05 07:33
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients 2023-09-28 07:38
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets 2023-09-21 07:05
Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis 2023-09-20 08:26
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy 2023-08-25 08:15
Everest Medicines Announces Interim Results for First Half of 2023 2023-08-24 08:15
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy 2023-08-21 08:20
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet 2023-08-18 08:41
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI) 2023-08-15 20:19
Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023 2023-08-09 08:06
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study 2023-08-01 08:47
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China 2023-07-27 08:10
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA ) 2023-06-21 08:15
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer 2023-06-16 07:45
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia 2023-05-17 07:48
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy 2023-05-12 07:40
Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy 2023-04-24 07:44
Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China 2023-04-19 08:12
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy 2023-04-06 07:30
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 2023-03-31 07:30
1 2 3 4 5 7